Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (Merck & Co., Inc.) (2025)

Government Record · Merck & Co., Inc. · February 25, 2025

Merck's 10-K reports Keytruda worldwide sales of $29.482 billion in 2024, $25.011 billion in 2023 and $20.937 billion in 2022, and states that Keytruda sales represented 46% of the company's total sales in 2024.

Keytruda 29,482 25,011 20,937

Item 7, MD&A – sales table (table row)

Merck's 10-K reports Keytruda worldwide sales of $29.482 billion in 2024, $25.011 billion in 2023 and $20.937 billion in 2022, and states that Keytruda sales represented 46% of the company's total sales in 2024. Company filing: no external funder; Merck is the maker of Keytruda. No comparator. EDGAR serves 10-K as HTM only, so pdf_url is empty by design. Quote is a revenue-table row (columns: 2024, 2023, 2022). The filing also flags IRA price-setting selection for 2026 and US compound patent expiry in December 2028.